Compass Therapeutics
CMPX
38 hedge funds and large institutions have $146M invested in Compass Therapeutics in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 4 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
12% more funds holding
Funds holding: 34 → 38 (+4)
2.13% more ownership
Funds ownership: 61.11% → 63.25% (+2.1%)
11% less capital invested
Capital invested by funds: $164M → $146M (-$18.3M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.43M |
| 3 |
BlackRock
New York
|
+$1.96M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.6M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$726K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$4.22M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.43M |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$80K |
| 4 |
MWM
Mascoma Wealth Management
Hanover,
New Hampshire
|
-$42K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$27.7K |
CMPX Hedge Fund Activity: Q3 2022 in Review
38 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q3 2022, worth a combined $146M — down 11% from $164M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CMPX positions and 4 closed out — a net gain of 5 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $3.05M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $4.22M sold.
- 38 institutional investors held Compass Therapeutics (CMPX) as of Q3 2022, up from 34 in Q2 2022.
- Funds reported $146M of Compass Therapeutics stock for Q3 2022, down 11% quarter-over-quarter.
- 9 funds opened new Compass Therapeutics positions in Q3 2022 and 4 closed out, a net change of +5 holders.
- The largest Compass Therapeutics buyer in Q3 2022 was Eventide Asset Management, an estimated $3.05M added.
- The largest Compass Therapeutics seller in Q3 2022 was Consonance Capital Management, an estimated $4.22M sold.
Based on aggregated 13F filings for Q3 2022.